Welcome to DailyUpdates Technology Channel: Dedicated to Biologics, Cell & Gene Therapies and Novel Approaches to Vaccines, Drug Delivery, Diagnostics & Drug Development - the R&D community's bulletin of breaking research, clinical trials and drug development news. This page will update each day. You have access for 1 more day(s). To receive DailyUpdates by e-mail register here

DailyUpdates by e-mail - the publication tracker for the drug discovery community

Technology Channel: Dedicated to Biologics, Cell & Gene Therapies and Novel Approaches to Vaccines, Drug Delivery, Diagnostics & Drug Development

---

---

• Recommend DailyUpdates
• Other Therapeutic Channels
• UpdatesPlus
• Consultancy
• Modify Subscription
• Past Content
• Submit to DailyUpdates
• Contact

	If this icon appears after any of our listed articles, the author is able to provide reprints. Articles denoted by an Licensing Op. icon describe data relevant to licensing opportunities. The report icon, , links through to full analyses relating to pharmaceutical/market developments relating to this work
Useful Links: Recommend DailyUpdates UpdatesPlus Consultancy Modify your subscription Search past content Submit a paper to DailyUpdates Contact LeadDiscovery	Today's journal articles Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. Effective siRNAs inhibit the replication of novel influenza A (H1N1) virus. Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know... New Clinical Trials Safety and Efficacy Study to Compare Capecitabine + Bevacizumab Versus Capecitabine, Concomitantly With Radiotherapy as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer (AVAXEL) Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer A Trial of Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type Non-Small-Cell Lung Cancer A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer Previous Journal Entries Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine. A Randomized, Controlled, Phase 2 Study of AMG 317, an IL-4R{alpha} Antagonist, in Patients with Asthma. Combination cytokine therapy inhibits tumor growth by generation of tumor-specific T-cell responses in a murine melanoma model. Delivery of paclitaxel by physically loading onto poly(ethylene glycol) (PEG)-graft-carbon nanotubes for potent cancer therapeutics. Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours. Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma. Partial and transient modulation of the CD3-T-cell receptor complex, elicited by low-dose regimens of monoclonal anti-CD3, is sufficient to induce disease remission in non-obese diabetic mice. The development, optimization and validation of an assay for high throughput antiviral drug screening against Dengue virus. Acceptability of switching adalimumab from a prefilled syringe to an autoinjection pen. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma. Biomarkers for predicting the sensitivity of cancer cells to TRAIL-R1 agonistic monoclonal antibody. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activity. Rational Design of Targeted Cancer Therapeutics through the Multiconjugation of Folate and Cleavable siRNA to RAFT-Synthesized (HPMA-s-APMA) Copolymers (dagger). Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. Lentivirus Immobilization to Nanoparticles for Enhanced and Localized Delivery From Hydrogels. Immunotherapy of breast cancer by single delivery with rAAV2-mediated interleukin-15 expression.	Today's News Items Inovio Biomedical Cervical Cancer Therapeutic Vaccine Generates Dose-Related Immune Response in Clinical Trial Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval Training Courses & Meetings No events listed Previous News Items Seattle Genetics and Millennium Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel Herceptin now approved in the EU for patients with HER2-positive advanced stomach cancer Teva Announces FDA Accepts BLA for XM02 For faster discovery, automatically organize PubMed results into categories